Four late-stage drug trials for in systemic lupus erythematosus (SLE) have results expected in 2022 or H1 2023, but lupus disease heterogeneity poses trial design challenges.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,